This is one of the California-based company's many transactions resulting from its royalty monetization strategy, noted an H.C. Wainwright & Co. report.
Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report.
First clinical data of this investigational interleukin-2 cytokine show it lacks the degree and rates of adverse events typically seen with treatments of this kind, noted an H.C. Wainwright & Co. report.
Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data, noted an Oppenheimer report.